GlassScriptPhysician profile
Glenn Alan Carr
NPI 1740566736
$5,069.08
in general payments reported to CMS, 2019-2025
36 companies · $18.03 in 2025
The $18.03 reported for 2025 was less than what a typical Hospice and Palliative Medicine (Internal Medicine) provider received nationally (typical 2025 total: $77.77).
See the full distribution for Hospice and Palliative Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $733 · 2021: $2,956 · 2022: $1,102 · 2023: $260 · 2025: $18.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $278.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $843.39 | 2020-2023 | Farxiga, Breztri |
| Abbvie INC. | $557.08 | 2020-2023 | Qulipta |
| Amgen INC. | $511.51 | 2020-2022 | |
| Novo Nordisk INC | $418.68 | 2020-2022 | |
| Pfizer INC. | $263.46 | 2020-2021 | |
| Glaxosmithkline, LLC. | $238.52 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $237.42 | 2020-2021 | |
| Lilly USA, LLC | $199.35 | 2020-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.83 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $156.28 | 2020-2021 | |
| Daiichi Sankyo INC. | $154.49 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $134.42 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.85 | 2021-2022 | |
| Esperion Therapeutics, INC. | $105.02 | 2020-2022 | |
| Sk Life Science, INC. | $97.05 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $93.86 | 2022 | |
| Boston Scientific Corporation | $91.92 | 2020-2022 | |
| Allergan, INC. | $83.75 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.62 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $69.98 | 2021 | |
| Abbott Laboratories | $66.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $59.30 | 2020-2021 | |
| Eisai INC. | $36.73 | 2020 | |
| Vbi Vaccine (Delaware) INC. | $35.86 | 2022-2023 | Prehevbrio |
| Dynavax Technologies Corporation | $34.86 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $32.36 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $31.29 | 2022 | |
| Janssen Pharmaceuticals, INC | $29.36 | 2021-2022 | |
| Radius Health, INC. | $25.39 | 2021 | |
| Almatica Pharma LLC | $25.06 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.77 | 2021 | |
| Medtronic, INC. | $18.03 | 2025 | Synchromedii |
| Astellas Pharma US INC | $17.53 | 2021 | |
| Nevro Corp. | $16.06 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.36 | 2020 | |
| Philips North America LLC | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.